Results 91 to 100 of about 2,302,822 (346)

A localising AdS$_3$ sigma model

open access: yesSciPost Physics
We construct a CFT with $\mathfrak{sl}(2,\mathbb{R})_k$ symmetry at the 'tensionless' point $k=3$, which is distinct from the usual $\mathrm{SL}(2,\mathbb{R})_{k=3}$ WZW model.
Lorenz Eberhardt, Matthias R. Gaberdiel
doaj   +1 more source

Cell density–dependent nuclear‐cytoplasmic shuttling of SETDB1 integrates with Hippo signaling to regulate YAP1‐mediated transcription

open access: yesFEBS Letters, EarlyView.
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom   +3 more
wiley   +1 more source

PSEUDODUALITY IN SUPERSYMMETRIC SIGMA MODELS [PDF]

open access: yesInternational Journal of Modern Physics A, 2010
We study the pseudoduality transformation in supersymmetric sigma models. We generalize the classical construction of pseudoduality transformation to supersymmetric case. We perform this both by component expansion method on manifold [Formula: see text] and by orthonormal coframe method on manifold [Formula: see text].
openaire   +2 more sources

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

open access: yesFEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson   +7 more
wiley   +1 more source

The theoretical study of $$p\bar{p}\rightarrow \bar{\Lambda }\Sigma \eta $$ p p ¯ → Λ ¯ Σ η reaction

open access: yesEuropean Physical Journal C: Particles and Fields
We study the production of hyperon resonances in the $$p\bar{p}\rightarrow \bar{\Lambda }\Sigma \eta $$ p p ¯ → Λ ¯ Σ η reaction within an effective Lagrangian approach.
Aojia Xu, Ruitian Li, Xuan Luo, Hao Sun
doaj   +1 more source

Estimating Mass of Sigma-Meson and Study on Application of the Linear Sigma-Model

open access: yes, 2004
Whether the $\sigma-meson$ ($f_0(600)$) exists as a real particle is a long-standing problem in both particle physics and nuclear physics. In this work, we analyze the deuteron binding energy in the linear $\sigma$ model and by fitting the data, we are ...
  +30 more
core   +2 more sources

Higher derivative sigma models

open access: yesJournal of High Energy Physics
Abstract We explore the nature of running couplings in the higher derivative linear and nonlinear sigma models and show that the results in dimensional regularization for the physical running couplings do not always match the values quoted in the literature.
John F. Donoghue, Gabriel Menezes
openaire   +2 more sources

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

Hyperon Single-Particle Potentials Calculated from SU6 Quark-Model Baryon-Baryon Interactions

open access: yes, 1999
Using the SU6 quark-model baryon-baryon interaction recently developed by the Kyoto-Niigata group, we calculate NN, Lambda N and Sigma N G-matrices in ordinary nuclear matter.
Bando   +55 more
core   +2 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy